AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2820155&ei=kXKaUoDPOcu40AHPMA&usg=AFQjCNFFl-0XiKsPgTfXLP961fJCu4C87Q
Amgen Inc To Acquire Onyx Pharmaceuticals Inc For $125 Per Share In Cash
Sunday, 25 Aug 2013 05:34pm EDT
Amgen Inc and Onyx Pharmaceuticals Inc announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. Amgen intends to effect the transaction through a tender offer and expects to close at the beginning of the fourth quarter, subject to the satisfaction of customary closing conditions, including the receipt of regulatory clearance. Amgen will finance the acquisition with $8.1 billion in committed bank loans and the balance with cash available in the U.S. The loans have five year terms and carry an average interest charge of LIBOR plus 104 basis points. Amgen expects to retain its investment grade credit rating following this transaction and remains committed to meaningfully increasing the dividend over time. Lazard is acting as lead advisor to Amgen; BofA Merrill Lynch is acting as co-advisor and is also lead arranger for the financing; and Sullivan & Cromwell LLP is serving as legal counsel. Centerview Partners, LLC is acting as financial advisor to Onyx and Goodwin Procter, LLP is serving as legal counsel.Â 
